Frontiers of biology in human diseases: strategies for biomolecule's discovery, nanobiotechnologies and biophotonics by Luiz Goulart et al.
ORAL PRESENTATION Open Access
Frontiers of biology in human diseases: strategies
for biomolecule’s discovery, nanobiotechnologies
and biophotonics
Luiz Goulart1*, Noelio Dantas2, Anielle Silva2, João Marcos Madurro3, Ana Graci Brito-Madurro4, Carlos Ueira-Vieira4,
Patricia Fujimura4, Yara Maia4, Paula Santos4, Ana Paula Freschi2,4, Juliana Almeida4, Isabela Goulart5
From 5th Congress of the Brazilian Biotechnology Society (SBBIOTEC)
Florianópolis, Brazil. 10-14 November 2013
Introduction
The current frontiers in biological sciences demand an
interface among disciplines of biology, chemistry, and
physics to achieve new paradigms in applied nanobio-
technologies to health. An extraordinary amount of
information on genomes, transcriptomes, proteomes,
metabolomes, miRNAs, lncRNAs, protein editing, post-
translational modifications, exosomes, molecular interac-
tions, cell signaling, structural biology, immunology, cel-
lular receptors, interactomes, and bioinformatics are
opening new possibilities for biological manipulations
aiming improved diagnostics and therapeutics. New
rationale is required to use available technologies that
intersect among imaging, electrochemistry, biophotonics,
nanotechnologies and combinatorial molecules. A mas-
sive, diverse and broad knowledge on multidisciplinary
aspects have been provided in the last few years, and
the challenge is to combine recent technologies and
information to identify revolutionary platforms for the
progression of life sciences. This brief review will discuss
examples of epitope-based and combinatorial antibody
and nucleic acid (aptamers) selection technologies in
association with nanobiotechnologies and their multiple
applications in biomedical sciences.
Discovery of biomarkers using combinatorial
technologies
Combinatorial libraries displaying very diverse set of
random peptides or very large repertoire of antibody
fragments’ fused to the capsid surface of filamentous
phage have been successfully exploited in the discovery
of novel biomarkers, and are excellent platforms for the
design of high-affinity, protein-based binding reagents.
Such markers are either peptide ligands that mimic epi-
tope regions (mimotope) or monoclonal antibody frag-
ments (Fab or scFv) against specific targets selected
through cycles of biopanning (binding-washing-elution-
transformation-amplification), also called Phage Display.
The fundamental advantage of this technology is the
direct link between the experimental phenotype and its
encapsulated genotype, which allows the evolution of
selected binders into optimized molecules [1,2]. Peptide
ligands may be used to map immunologically active
sites in proteins, carbohydrates, lipids, and also as indi-
vidual epitope-mimicking antigens and immunogens
[3,4]. The selected mimotopes may also be directly used
in phage-based ELISA immunoassays, resulting in sim-
ple, specific, sensitive, and low-cost immunodiagnostic
tests [5]. Similarly, the selection of antibodies from com-
binatorial libraries has also become an important tool
for the generation of reagents, diagnostics, and thera-
peutic molecules. It is the only method to obtain speci-
fic antibodies bypassing the immunization step, which
mimics the maturation process of human antibody in
vivo, resulting in high affinity antibody ligands, which
may be suitable to human administration and potentially
applicable to clinical diagnosis and treatment. We have
generated successful molecules for diagnostic [5-8] and
therapeutic [7,9] purposes through phage display by in
vitro, ex vivo and in vivo approaches of selection. Such
strategies are dependent on a very stringent subtractive
selection scheme that includes well-characterized target
samples and controls, target purification, elution/wash-
ing protocol with or without competitor molecules,
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number of selection cycles, and quality of the library
and its diversity.
Another important combinatorial technology is the
selection of aptamers, which are random RNA or DNA
sequences with conformational actions that specifically
bind to a variety of targets, including proteins, small mole-
cules, oligonucleotides, and peptides. In RNA aptamer
selections, a DNA pool containing random sequences is
typically synthesized artificially, which are subsequently
transcribed to give the starting RNA population. Aptamer
ligands are then evolved during several cycles of selection,
elution, PCR amplification, cloning and transformation.
Among several advantages of aptamers over other com-
mon biomarkers, we can include the similar molecular
recognition of antibodies, the ability to be completely engi-
neered in test tubes, the chemical synthesis at very low
costs, desirable storage features due to their resistance to
high temperatures and humidity without degradation, lack
of immunogenicity, high potency and specificity. We have
successfully selected aptamers for prostate cancer diagno-
sis, and to validate its potential use, magnetic beads were
functionalized with our novel aptamer that promptly
recognized circulating tumor cells, and can be an auxiliary
tool for molecular diagnostics.
Briefly, short peptides, antibody fragments and aptamers
aiming the selection of functional core sequences of epi-
tope or paratope targets can be used in combination with
nanotechnologies and biophotonics for improvement of
diagnostic platforms, which will be further explored.
Electrochemistry
Biosensors combine the biological nature of markers
with the power of microelectronics and optoelectronics
to offer powerful analytical tools with major applications
in medical diagnostics. The foundations of biological
sensors’ technology involve the interplay of fundamental
disciplines, demanding specific knowledge on physical
chemistry (nanoparticles), materials science (polymers),
physics (optics and solid state), biology (antigen, anti-
body, biochemistry, genetics, substrates, and clinical
information of diseases) and engineering (electronics
and microfabrication). The specific interaction between
the target analyte and the complementary recognition
layer functionalized with a biomarker produces a phy-
sico-chemical change that is detected and measured by
an electrochemical transducer through electric altera-
tions as voltage (voltammetry), current (amperometry)
or resistance (impedance). We have developed specific
biosensors for nucleic acids and proteins detection using
electrochemistry technology for dengue virus, leishma-
niasis, leprosy, breast and prostate cancer, and many
other diseases [8,10]. Our aim is to translate these para-
meters into a universal platform using specific polymers
as electrodes that not only allow prompt conjugation of
biomarkers, but also mediate electron transfer kinetics
to achieve a faster response in a simple, portable, speci-
fic and sensitive instrument. However, other technolo-
gies are also very competitive in the diagnostic field, due
to specific functionalities and uses, such as target cap-
ture and enrichment by magnetic nanoparticles [10],
imaging mediated by quantum dots, and other biopho-
tonic technologies for the improvement of conventional
assays, which is further discussed.
Nanoparticles and biophotonics
Microparticle agglutination test has been used in clinical
diagnostics since 1980’s. However, nanoparticles only
recently became important diagnostic tools due to the
development of different synthesis routes, chemical
groups and polymers. Our first approaches with nanopar-
ticles were focused on agglutination assays, specifically
with colored-latex Particle Gel Immunoagglutination test
(PaGIa) and Magnetic Microparticle-ELISA (MME) for
antigen and antibody detection. The agglutination tests
were performed with microparticles and nanoparticles
coupled with filamentous bacteriophages displaying fused
mimotopes on its surface, which has favored the forma-
tion of the antigen-antibody or peptide-protein com-
plexes, amplifying the optical detection in ELISA assays
or after the chromatographic separation of the microag-
glutinates [10].
Different from latex nanoparticles, a new class of semi-
conductor nanocrystals, called Quantum Dots (QDs) has
been developed with potential applications in diagnosis,
drug delivery, biomedical imaging, sensors and optoelec-
tronics. However, QDs are still considered toxic due to the
use of hazardous reagents and synthesis under high tem-
peratures, which affect their stability and biocompatibility.
These QDs are highly luminescent and their emission
wavelengths are dependent on their diameter, varying
from 2 to 20 nm. Recently, our group has synthesized a
novel class of ultrasmall QDs through an aqueous phase
route (green chemistry), also called magic-sized QD.
These extremely small nanocrystals present diameters
below 2 nm, are highly stable, non-toxic, non-immuno-
genic, and with proper functionalization may become a
powerful biomarker that may be used in many different
applications, including immunohistochemistry and in vivo
imaging studies, as shown with a breast cancer cell line.
Interestingly, other biophotonic technologies have also
the potential to be used in clinical and laboratory settings.
We have explored the surface plasmon resonance (SPR)
technology to improve the conventional ELISA tests of
many different diseases. Surface plasmons are surface elec-
tromagnetic waves that propagate in a direction parallel
to the metal/dielectric interface, usually formed with
gold nanofilms. The wave is on the boundary of the gold
polymer with the external medium (sample), and these
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oscillations are very sensitive to any changes of this
boundary, such as the adsorption of molecules to the
functionalized gold surface. The technology relies on
reflectivity measurements used to detect DNA or proteins
by changes in the local index of refraction upon adsorp-
tion of the target molecule to the functionalized gold sur-
face without labeling. We have reached very high
sensitivity using specific phage display-derived biomarkers
for leprosy and dengue virus detection, which are diseases
with diagnostic problems due to their nature and specific
clinical conditions, and results indicate that simple SPR
systems can substitute conventional ELISA tests in the
near future.
Conclusion and perspectives
We have successfully shown that combinatorial technol-
ogies have revealed functional determinant sites of
molecules, which were combined with multiple research
tools, techniques, and instruments that enabled entirely
novel approaches for diagnostics and therapeutics.
We believe that extensive and global analytical techni-
ques, such as genomics and proteomics, may allow
major target identification, but cross-reactions still
remain as a problem, which can be solved by reducing
the target site, a goal that has been promptly achieved
by Phage display or Aptamer selections.
The search for universal and robust diagnostic plat-
forms and for highly specific and sensitive markers have
been the highest challenges in the medical field, due to
the variable disease spectra, different pathogenetic back-
grounds, specific sampling, the complex interactions
with vectors and environments, which may result in
very diverse phenotypes [10]. Only multidisciplinary
teams and novel nanobiotechnological approaches can
meet the demand of smart solutions for human diseases
diagnostics.
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